First-in-human, First-in-class Phase 1a Study of BXQ-350 for Solid Tumors and Gliomas.
> View

Absence of Indicators of Hypercoagulability and Anti-phospholipid Syndrome in BXQ-350 First in Human Study.
> View

Allometric Scaling of Preclinical Pharmacokinetic and Toxicokinetic Parameters to Predict Clinical Pharmacokinetics of BXQ-350 Saposin C Protein-Phosphatidylserine Nanovesicles.
> View

Combined Effect of Gemcitabine (GEM) and SapC-DOPS Nanovesicles on Pancreatic Ductal Adenocarcinoma (PDAC) in Mice.
> View

Safety and Pharmacokinetics of BXQ-350 in a Phase 1a and 1b Trial of Solid Tumors and High-grade Glioma.
> View

High-Grade Glioma outcomes in the Phase 1 BXQ-350 trial of cancer-selective SapC-DOPS nanovesicles
> View

Trial in Progress: A Phase 1 Open Label, Multi-Center Study to Evaluate the Safety and Tolerability of BXQ-350 in Children with Newly Diagnosed Diffuse Intrinsic Pontine Glioma (DIPG) and Diffuse Midline Glioma (DMG)with H3K27M alteration
> View

BXQ-350 Shows Signs of Potential Activity in Ependymoma Patients
> View

BXQ-350 for the Treatment of Solid Tumors: Modulating Ceramides and Sphingosine-1-Phosphate
> View

A Pediatric and Young Adult Phase I Dose Escalation Safety Study of BXQ-350 for Refractory Solid and Central Nervous System Tumors
> View

BXQ-350 targets to the lysosome and kills glioblastoma (GBM) cells via activation of apoptotic caspases in vitro.
> View

Outcomes of High-Grade Glioma Patients in a Phase 1 Trial of BXQ-350, Cancer-selective SapC-DOPS Nanovesicles
> View

First-in-human, First-in-Class Phase 1a Study of BXQ-350 for Solid Tumors and Gliomas
> View

• Red Arrows indicate the initial target lesion that decreased in size while on study
• Blue Arrows indicate new area of enhancement
• Note: Surgery in May, 2018 revealed significant treatment effect with only trace tumor cells present. As of September, 2019 patient continues on study having completed 3 years in the trial.

• Axial T1-post contrast (Ax SE T1 POST FC) 1.5T MRI of the brain of a 64-yr old male patient with glioblastoma (GBM) treated with BXQ-350. GBM was first diagnosed in 2013 and previously treated with surgery, chemotherapy and radiation. Measurable lesion reduction over time is apparent in the anterior corpus callosum and frontal lobe, with those bordering the ventricle.

• 65-yr old female with rGBM
• GBM diagnosed in March 2017 (stage IV) previously treated with surgery, chemotherapy and radiation
• Rapid progression (2M) prior to starting BXQ-350 in May 2018
• 1 target lesion (L parietal) 1.4 cm at Screening down to 0.36 cm at Day 56 (-74%)
• Progressed after 948 days on BXQ-350